Tasicap 150 mg & 200 mg Capsules.
PDF Leaflet Revision Date: April 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with Ph+ CML in chronic and accelerated phases.
Dosage (summary)
300 mg twice daily for newly diagnosed Ph+ CML; 400 mg twice daily for resistant/intolerant Ph+ CML.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; use contraception. Unknown if excreted in breast milk.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to nilotinib
Common side effects
- Rash
- Nausea
- Fatigue
- Headache
- Myalgia
Counselling Points
- Take on an empty stomach
- Monitor for signs of cardiac issues
- Report any severe side effects immediately
Serious warnings
- QT prolongation
- Myelosuppression
- Hepatitis B reactivation
Important Disclaimer
The Tasicap 150 mg & 200 mg Capsules. professional information leaflet below is the property of Hetero Drugs South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
